Objective: To evaluate the early and med-term outcomes of transplantation of autologous bone marrow mesenchymal stem cells（BMSCs） and mononucleus cells（BMMNCs） to treat coronary heart disease. Methods: Fourteen patients with coronary heart disease complicated with myocardial infarction were enrolled in this prospective, nonrandomized, control study（8 patients in cell transplantation group, 6 in control group）. BMSCs and BMMNCs were isolated and cultured for 2-3 weeks, and （0.9-3.5） × 106 BMSCs plus（1.6-6.1） × 106 BMMNCs were transplanted into the myocardial infracted area in cell transplantation group through intracoronary way. All patients underwent 3-month and 8-month follow-up for 6 minutes test, 2D Doppler echocardiogram and SPECT. Results: After 3 months and 8 months follow-up, cardiac function was improved. Six minutes distance was prolonged from 320.72 ± 60.47 to 406.88 ± 68.31 and 484.79 ± 81.00. Left ventricular ejection fraction（LVEF） was increased from 42.5% to 49.5% and 54%. The infarct defected regions was reduced from 45.5% to 39% and 25% in 6 patients with anterior myocardial infarction. In control group, 2D Doppler echocardiogram and SPECT were improved in 3 months but not improved 8 months after PCI. In cell transplantation group, 2 patients with inferior myocardial infarction had no significant efficacy. Conclusion: The preliminary study showed that in the patients with coronary heart disease complicated with anterior myocardial infarction, transplantation of BMSCs and BMMNCs could improve cardiac function and cardiac metabolism. The effects could last 8 months.